Amgen (AMGN) Non-Current Debt (2009 - 2026)

Amgen has reported Non-Current Debt for 18 years, with the latest figure at $57.3 billion in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 1.96% year-over-year to $57.3 billion in Q2 2026; TTM through Jun 2026 was $57.3 billion, a 1.96% increase from a year earlier, with the FY2025 full-year figure at $54.6 billion, down 9.14% from the prior year.
• Non-Current Debt was $57.3 billion for Q2 2026 at Amgen, roughly flat from $57.3 billion in the prior quarter.
• The five-year high for Non-Current Debt was $64.6 billion in Q4 2023, with the low at $36.5 billion in Q2 2022.
• Average Non-Current Debt over 5 years is $54.7 billion, with a median of $57.4 billion recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 68.51% in 2023, then declined 10.37% in 2025.
• Over 5 years, Non-Current Debt stood at $38.9 billion in 2022, then surged by 65.91% to $64.6 billion in 2023, then dropped by 6.99% to $60.1 billion in 2024, then declined by 9.14% to $54.6 billion in 2025, then rose by 4.94% to $57.3 billion in 2026.
• The last three Non-Current Debt figures came in at $57.3 billion (Q2 2026), $57.3 billion (Q1 2026), and $54.6 billion (Q4 2025), per Business Quant data.